ReviewBritish journal of haematology2012
Childhood acute myeloid leukaemia.
Review in British journal of haematology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Body Mass Index at Pediatric Leukemia Diagnosis and the Risks of Relapse and Mortality: Findings from a Single Institution and Meta-analysis.Journal of obesity · 2018Pooled it
- Improvement in Outcomes of Childhood Acute Myeloid Leukemia Treatment: A Survival Analysis at a Reference University Hospital in Rio de Janeiro, Brazil.Cancer reports (Hoboken, N.J.) · 2026Article
- Genetic landscape of pediatric acute myeloid leukemia in Taiwan.Scientific reports · 2026Article
- Treatment outcomes and prognostic factors in children diagnosed with acute myeloid leukaemia in Uganda.BMC cancer · 2025Article
- Clinical outcomes of allogeneic hematopoietic stem cell transplant with different stem cell sources in infant acute myeloid leukemia.Scientific reports · 2025Article
- Article
- Graft CD8International journal of hematology · 2025Article
- Moving forward in target antigen discovery for immunotherapy in acute myeloid leukemia.Haematologica · 2024Article
- Treatment outcomes of pediatrics acute myeloid leukemia (AML) and associated factors in the country's tertiary referral hospital, Ethiopia.BMC cancer · 2024Article
- Pediatric acute myeloid leukemia and hyperleukocytosis with WBC count greater than 50 × 10International journal of hematology · 2023Article
- MicroRNA profiling of paediatric AML withOncology reports · 2022Article
- EAHP 2020 workshop proceedings, pediatric myeloid neoplasms.Virchows Archiv : an international journal of pathology · 2022Article
- Neurocognitive deficits in survivors of childhood acute myeloid leukemia.BMC pediatrics · 2022Article
- Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group.Pediatric blood & cancer · 2022Article
- The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia.Journal of clinical medicine · 2021Review
- Article
- Article
- Treatment outcomes of pediatric acute myeloid leukemia: a retrospective analysis from 1996 to 2019 in Taiwan.Scientific reports · 2021Article
- Prognostic Factors in Childhood Acute Myeloid Leukemia; Experience from A Developing Country.Cancer reports (Hoboken, N.J.) · 2020Article
- Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.Cancers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Although acute myeloid leukaemia (AML) has long been recognized for its morphological and cytogenetic heterogeneity, recent high-resolution genomic profiling has demonstrated a complexity even greater than previously imagined. This complexity can be seen in the number and diversity of genetic alterations, epigenetic modifications, and characteristics of the leukaemic stem cells. The broad range of abnormalities across different AML subtypes suggests that improvements in clinical outcome will require the development of targeted therapies for each subtype of disease and the design of novel clinical trials to test these strategies. It is highly unlikely that further gains in long-term survival rates will be possible by mere intensification of conventional chemotherapy. In this review, we summarize recent studies that provide new insight into the genetics and biology of AML, discuss risk stratification and therapy for this disease, and profile some of the therapeutic agents currently under investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.